Kathleen Tregoning Purchases SPRO Shares
Kathleen Tregoning acquired 10,000 shares of SPRO on June 23, 2026.
Key Points
- Kathleen Tregoning bought 10,000 shares of SPRO on June 23, 2026.
- SPRO traded at $2.02 on Friday with no significant P/E ratio.
- Vanguard Capital Management opened a new position in SPRO with 1,799,880 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kathleen Tregoning purchased 10,000 shares of SPRO on June 23, 2026. The transaction was not pre-planned and comes as part of a series of insider buys on the same day.
Insider Buying and Selling at Spero Therapeutics, Inc.
Several insiders at SPRO made significant purchases on June 23, 2026. Jackson Scott Thomas, John Pottage Jr, Milind Deshpande, Cynthia Smith, Patrick V.J.J. Vink, and Frank Thomas each bought shares ranging from 10,000 to 20,000. These transactions were not part of any pre-arranged trading plans.
Other Institutional Activity in SPRO
Vanguard Capital Management LLC opened a new position in SPRO, acquiring 1,799,880 shares valued at approximately $4.21 million. Renaissance Technologies LLC reduced its holdings by 90,287 shares, leaving it with 1,189,235 shares worth about $2.78 million, marking a 7.1% decrease. Two Sigma Investments, LP significantly increased its stake by 513,061 shares, now holding 885,631 shares valued at $2.07 million, representing a 137.7% increase.
Spero Therapeutics, Inc. Stock Up 68.3%
Shares of SPRO traded at $2.02 on Friday. The stock does not currently have a meaningful P/E ratio as it is not profitable. SPRO's market performance includes a 52-week low of $1.50 and a high of $3.50. The stock's 50-day moving average is $2.10, while the 200-day moving average stands at $2.30.
$SPRO stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On January 30, 2025, HC Wainwright & Co. reiterated its buy rating for SPRO with a price target of $5.00. Evercore ISI Group downgraded the stock to hold with the same target price on December 20, 2024. Previously, HC Wainwright & Co. had reiterated its buy rating multiple times, with targets ranging from $5.00 to $7.00.
Bottom Line
Kathleen Tregoning's purchase of SPRO shares adds to a series of insider buys, indicating confidence in the company's prospects. Investors often track insider transactions for potential insights, although these filings are backward-looking and may not reflect current positions. Institutional activity and analyst ratings provide additional context for SPRO's market standing.
Get Spero Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.